Another small clinical study of lung cancer samples before and after PD-1 inhibitor treatment found that the CD8+ tumor-infiltrating lymphocytes related to cytotoxic function (PRF1, GZMB, and GZMH) and activation (CD38) increased in posttreatment patients [261]. The gene discussed is PDCD1; the disease is lung carcinoma.